KB-1158

Theralizumab

Background

The CD28 molecule is a member of the Ig superfamily and is expressed as a homodimer composed of two peptide chains on the surface of CD4+ T cells and more than half of CD8+ T cells. Theralizumab(TGN1412) was a promising therapeutic agent that yielded outstanding results in both in vitro studies and animal trials. It is a CD28 superagonist monoclonal antibody that activates T regulatory (TReg) cells in the absence of costimulation of the T cell receptor (TCR) by an antigen-presenting cell. This drug was intended as a solution to T cell deficient diseases such as B cell leukemia and autoimmune diseases such as rheumatoid arthritis.

Specifications

Catalog Number:
KB-1158
Cell Line Name:
Theralizumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
CD28
Species Reactivity:
Human
Application:
ELISA | KD
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA | KD

References

1.Dmitry Tyrsin , Sergey Chuvpilo , Alexey Matskevich , Daniil Nemenov , Paula S Römer , Paula Tabares , Thomas Hünig. From TGN1412 to TAB08:the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis. Clin Exp Rheumatol.2016 Jul-Aug;34(4 Suppl 98):45-8 Katelyn E Brown . Revisiting CD28 Superagonist TGN1412 as Potential Therapeutic for Pediatric B Cell Leukemia: A Review. Diseases. 2018 May 19;6(2):4
Please enable JavaScript in your browser to complete this form.